Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke.

Toomey JR, Valocik RE, Koster PF, Gabriel MA, McVey M, Hart TK, Ohlstein EH, Parsons AA, Barone FC.

Stroke. 2002 Feb;33(2):578-85.

PMID:
11823673
2.

Inhibition of factor Xa reduces ischemic brain damage after thromboembolic stroke in rats.

Wang X, Xu L, Wang H, Grzanna R, Zhan Y, Knabb RM, Luettgen JM, Bozarth TA, Galemmo RA, Wong PC, Bernard R, Vargas H, Chopp M, Friedman SM, Feuerstein GZ.

Stroke. 2003 Feb;34(2):468-74.

PMID:
12574562
3.
4.

Effects of tissue type plasminogen activator in embolic versus mechanical models of focal cerebral ischemia in rats.

Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH, Lo EH.

J Cereb Blood Flow Metab. 1999 Dec;19(12):1316-21.

PMID:
10598935
7.

An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.

Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV.

Stroke. 2012 Sep;43(9):2444-9. doi: 10.1161/STROKEAHA.112.658997. Epub 2012 Jul 17.

8.

Adjuvant treatment with a glycoprotein IIb/IIIa receptor inhibitor increases the therapeutic window for low-dose tissue plasminogen activator administration in a rat model of embolic stroke.

Zhang L, Zhang ZG, Zhang R, Morris D, Lu M, Coller BS, Chopp M.

Circulation. 2003 Jun 10;107(22):2837-43. Epub 2003 May 19.

PMID:
12756151
10.

Effective and safe conditions of low-frequency transcranial ultrasonic thrombolysis for acute ischemic stroke: neurologic and histologic evaluation in a rat middle cerebral artery stroke model.

Saguchi T, Onoue H, Urashima M, Ishibashi T, Abe T, Furuhata H.

Stroke. 2008 Mar;39(3):1007-11. doi: 10.1161/STROKEAHA.107.496117. Epub 2008 Jan 31.

PMID:
18239172
11.
12.

THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models.

Krakovsky M, Polianski V, Nimrod A, Higazi A, Leker RR, Lamensdorf I.

Neurol Res. 2011 Nov;33(9):983-90. doi: 10.1179/1743132811Y.0000000018.

PMID:
22081002
13.

Opening the window: Ischemic postconditioning reduces the hyperemic response of delayed tissue plasminogen activator and extends its therapeutic time window in an embolic stroke model.

Esmaeeli-Nadimi A, Kennedy D, Allahtavakoli M.

Eur J Pharmacol. 2015 Oct 5;764:55-62. doi: 10.1016/j.ejphar.2015.06.043. Epub 2015 Jun 27.

PMID:
26123846
14.

Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.

Liu W, Hendren J, Qin XJ, Liu KJ.

Stroke. 2009 Jul;40(7):2526-31. doi: 10.1161/STROKEAHA.108.545483. Epub 2009 May 28.

16.
17.

Extension of Tissue Plasminogen Activator Treatment Window by Granulocyte-Colony Stimulating Factor in a Thromboembolic Rat Model of Stroke.

Dela Peña IC, Yang S, Shen G, Fang Liang H, Solak S, Borlongan CV.

Int J Mol Sci. 2018 May 31;19(6). pii: E1635. doi: 10.3390/ijms19061635.

18.

Tissue plasminogen activator treatment of stroke in type-1 diabetes rats.

Ning R, Chopp M, Yan T, Zacharek A, Zhang C, Roberts C, Cui X, Lu M, Chen J.

Neuroscience. 2012 Oct 11;222:326-32. doi: 10.1016/j.neuroscience.2012.07.018. Epub 2012 Jul 20.

19.
20.

Effects of a TAFI-inhibitor combined with a suboptimal dose of rtPA in a murine thromboembolic model of stroke.

Durand A, Chauveau F, Cho TH, Kallus C, Wagner M, Boutitie F, Maucort-Boulch D, Berthezène Y, Wiart M, Nighoghossian N.

Cerebrovasc Dis. 2014;38(4):268-75. doi: 10.1159/000366266. Epub 2014 Nov 13.

PMID:
25401979

Supplemental Content

Support Center